Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Achilles Therapeutics

07.10.2020

Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Professor Karl Peggs as Chief Medical Officer (CMO) with effect from 4th January 2021. Professor Peggs is an internationally recognised leader in the field of cancer immunology and a founder of the Company.
Achilles Therapeutics

07.07.2020

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.
Achilles Therapeutics

23.06.2020

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.
Achilles Therapeutics

02.06.2020

Achilles - Jefferies Healthcare Conference Presentation

Download (2.72Mb)
Achilles Therapeutics

29.05.2020

Achilles Doses First Patient

Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy
Achilles Therapeutics

29.05.2020

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens (1)

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma. This is the first tumour-infiltrating lymphocyte (TIL) therapy to enter clinical trials where the TILs have been specifically selected to target clonal neoantigens – antigens which are believed to be present on all tumour cells.
Achilles Therapeutics

13.05.2020

Achilles Therapeutics announces formation of Scientific Advisory Board

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumor target, today announced the formation of a Scientific Advisory Board (SAB) with three world-renowned appointments: Dr Elizabeth M. Jaffee, Dr Scott Antonia and Dr Christopher A. Klebanoff. The SAB will work closely with Achilles’ senior management team and Founders to advance the Company’s pipeline of solid tumor cancer therapies.
Achilles Therapeutics

22.04.2020

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced that it will present a manufacturing update using the VELOSTM manufacturing platform for its lead programs at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.
Achilles Therapeutics

07.04.2020

Achilles Therapeutics appoints Carsten Boess to the Board of Directors

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Carsten Boess as Non-Executive Director to its Board, effective 1 April 2020.
Achilles Therapeutics

17.03.2020

Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer

Achilles Therapeutics (“Achilles”), a clinical stage oncology company developing personalised cell therapies targeting clonal neoantigens (a novel class of tumour target), today announced the appointment of Professor Sergio Quezada as Chief Scientific Officer (CSO) with effect from 6 April 2020.

Load More